Natixis Has $9.86 Million Stake in Insulet Co. (PODD)

Natixis grew its position in shares of Insulet Co. (NASDAQ:PODD) by 61.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 113,692 shares of the medical instruments supplier’s stock after purchasing an additional 43,173 shares during the period. Natixis owned approximately 0.19% of Insulet worth $9,855,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of PODD. Blair William & Co. IL increased its stake in shares of Insulet by 44.1% in the first quarter. Blair William & Co. IL now owns 10,103 shares of the medical instruments supplier’s stock worth $876,000 after buying an additional 3,093 shares during the last quarter. UBS Group AG increased its stake in shares of Insulet by 194.9% in the first quarter. UBS Group AG now owns 10,687 shares of the medical instruments supplier’s stock worth $926,000 after buying an additional 7,063 shares during the last quarter. Lord Abbett & CO. LLC increased its stake in shares of Insulet by 2.9% in the first quarter. Lord Abbett & CO. LLC now owns 1,208,861 shares of the medical instruments supplier’s stock worth $104,784,000 after buying an additional 34,025 shares during the last quarter. Lisanti Capital Growth LLC increased its stake in shares of Insulet by 36.6% in the first quarter. Lisanti Capital Growth LLC now owns 63,460 shares of the medical instruments supplier’s stock worth $5,501,000 after buying an additional 17,020 shares during the last quarter. Finally, Next Century Growth Investors LLC increased its stake in shares of Insulet by 70.7% in the first quarter. Next Century Growth Investors LLC now owns 150,309 shares of the medical instruments supplier’s stock worth $13,028,000 after buying an additional 62,255 shares during the last quarter.

In other news, SVP Michael P. Spears sold 7,496 shares of the business’s stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $100.00, for a total transaction of $749,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David A. Lemoine sold 1,084 shares of the business’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $84.93, for a total transaction of $92,064.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,277 shares of company stock valued at $3,875,186. Corporate insiders own 3.60% of the company’s stock.

A number of analysts recently issued reports on PODD shares. Zacks Investment Research upgraded shares of Insulet from a “sell” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Tuesday, May 8th. Barclays reiterated an “overweight” rating and set a $90.00 target price (up previously from $85.00) on shares of Insulet in a research note on Thursday, February 22nd. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 23rd. Berenberg Bank began coverage on shares of Insulet in a research note on Friday, April 20th. They set a “buy” rating and a $100.00 target price for the company. Finally, ValuEngine upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $90.18.

Shares of Insulet opened at $97.39 on Friday, according to Marketbeat. Insulet Co. has a 1 year low of $46.27 and a 1 year high of $102.89. The firm has a market cap of $5.72 billion, a PE ratio of -211.72 and a beta of 1.37. The company has a debt-to-equity ratio of 3.34, a current ratio of 5.48 and a quick ratio of 5.16.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.08. Insulet had a negative net margin of 4.82% and a negative return on equity of 20.02%. The company had revenue of $123.60 million during the quarter, compared to the consensus estimate of $121.76 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 21.5% compared to the same quarter last year. analysts anticipate that Insulet Co. will post -0.18 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply